Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 3 Lymphoma, Non-Hodgkin 2 Carcinoma, Basal Cell 2 Basal Cell Nevus Syndrome 2 Upper Tract Urothelial Carcinomas 1 Solid Tumors 1 Serous Ovarian Cancer 1 Recurrence 1 Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1 Ovarian Neoplasms 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Amyloidosis 1

Interventions

Bevacizumab 187 Fluorouracil 150 Leucovorin 135 Cetuximab 127 Irinotecan 114 Oxaliplatin 108 pembrolizumab 96 Capecitabine 82 IFL protocol 53 Panitumumab 43 Nivolumab 43 regorafenib 42 Folfox protocol 39 Gemcitabine 30 trifluridine tipiracil drug combination 27 Cisplatin 24 Carboplatin 24 atezolizumab 23 Pemetrexed 20 Paclitaxel 20 Drug Therapy 20 130-nm albumin-bound paclitaxel 17 Trastuzumab 14 encorafenib 13 Trifluridine 13 Ipilimumab 13 HMPL-013 13 tislelizumab 12 spartalizumab 11 Docetaxel 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colorectal Neoplasms × Drug Evaluation × Clear all

NCT05189171 2024-06-28

MODEL-CRC

Xilis, Inc.

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡